Literature DB >> 32737765

Well-tempered MCMC simulations for population pharmacokinetic models.

Frederic Y Bois1, Nan-Hung Hsieh2, Wang Gao3, Weihsueh A Chiu2, Brad Reisfeld4.   

Abstract

A full Bayesian statistical treatment of complex pharmacokinetic or pharmacodynamic models, in particular in a population context, gives access to powerful inference, including on model structure. Markov Chain Monte Carlo (MCMC) samplers are typically used to estimate the joint posterior parameter distribution of interest. Among MCMC samplers, the simulated tempering algorithm (TMCMC) has a number of advantages: it can sample from sharp multi-modal posteriors; it provides insight into identifiability issues useful for model simplification; it can be used to compute accurate Bayes factors for model choice; the simulated Markov chains mix quickly and have assured convergence in certain conditions. The main challenge when implementing this approach is to find an adequate scale of auxiliary inverse temperatures (perks) and associated scaling constants. We solved that problem by adaptive stochastic optimization and describe our implementation of TMCMC sampling in the GNU MCSim software. Once a grid of perks is obtained, it is easy to perform posterior-tempered MCMC sampling or likelihood-tempered MCMC (thermodynamic integration, which bridges the joint prior and the posterior parameter distributions, with assured convergence of a single sampling chain). We compare TMCMC to other samplers and demonstrate its efficient sampling of multi-modal posteriors and calculation of Bayes factors in two stylized case-studies and two realistic population pharmacokinetic inference problems, one of them involving a large PBPK model.

Entities:  

Keywords:  Bayes factor; Bayesian inference; Thermodynamic integration; computational efficiency; physiologically-based pharmacokinetic model; population pharmacokinetics

Year:  2020        PMID: 32737765      PMCID: PMC8082542          DOI: 10.1007/s10928-020-09705-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  BioBayes: a software package for Bayesian inference in systems biology.

Authors:  Vladislav Vyshemirsky; Mark Girolami
Journal:  Bioinformatics       Date:  2008-07-16       Impact factor: 6.937

3.  GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models.

Authors:  Frédéric Y Bois
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

Review 4.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach.

Authors:  Todd J Zurlinden; Brad Reisfeld
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-01-31       Impact factor: 2.441

6.  Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.

Authors:  Xinyuan Zhang; Robert A Lionberger; Barbara M Davit; Lawrence X Yu
Journal:  AAPS J       Date:  2011-01-05       Impact factor: 4.009

7.  Pharmacokinetics of intravenous theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

8.  Pharmacokinetics of a sustained-release theophylline formulation.

Authors:  P W Trembath; S W Boobois
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

9.  Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling.

Authors:  Céline Brochot; Maribel Casas; Cyntia Manzano-Salgado; Florence A Zeman; Thomas Schettgen; Martine Vrijheid; Frédéric Y Bois
Journal:  Toxicol Appl Pharmacol       Date:  2019-06-26       Impact factor: 4.219

10.  Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells.

Authors:  Jérémy Hamon; Paul Jennings; Frederic Y Bois
Journal:  BMC Syst Biol       Date:  2014-06-25
View more
  2 in total

1.  Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

Authors:  Janak R Wedagedera; Anthonia Afuape; Siri Kalyan Chirumamilla; Hiroshi Momiji; Robert Leary; Mike Dunlavey; Richard Matthews; Khaled Abduljalil; Masoud Jamei; Frederic Y Bois
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-22

2.  A Population-Based Human In Vitro Approach to Quantify Inter-Individual Variability in Responses to Chemical Mixtures.

Authors:  Lucie C Ford; Suji Jang; Zunwei Chen; Yi-Hui Zhou; Paul J Gallins; Fred A Wright; Weihsueh A Chiu; Ivan Rusyn
Journal:  Toxics       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.